XML 68 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0 $ 0
Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High 741 741
Acquisition Related Contingent Consideration [Member]    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Business Combination, Contingent Consideration, Liability 160 160
Acquisition Related Contingent Consideration [Member] | Level 3 [Member]    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Payments for contingent consideration   25
Acquisition-Related Contingent Consideration [Roll Forward]    
Balance at beginning of period   (153)
Milestone payments   25
Change in fair value   (32)
Balance at end of period (160) $ (160)
Acquisition Related Contingent Consideration [Member] | Minimum [Member] | Level 3 [Member]    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Fair Value Inputs, Cost of Debt   4.70%
Fair Value Inputs, Weighted Average Cost of Capital   10.00%
Acquisition Related Contingent Consideration [Member] | Maximum [Member] | Level 3 [Member]    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Fair Value Inputs, Weighted Average Cost of Capital   21.00%
Enobia Pharma Corp. [Member]    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Payments for contingent consideration 25  
Acquisition-Related Contingent Consideration [Roll Forward]    
Milestone payments $ 25